Skip to main content
OpenTrials
Completed

NCT Number: NCT06102915

Rocuronium vs Cis-atracurium: Do Rocuronium Still 'ROCKS' In Coronary Artery Bypass Grafting

The current trend in most cardiac surgeries was to use rocuronium as it provides faster recovery in train-of-four ratio compared to other aminosteroid non-depolarising neuromuscular blocker. However, as most cardiac centres' standard of care does not perform any neuromuscular monitoring nor antagonism of neuromuscular blockade effect, residual neuromuscular blockade could potentially be the key to delayed extubation. As such, Cis-atracurium's organ-independent Hofmann elimination could be in favour.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Neuromuscular Blockade Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Artery Bypass Grafting Coronary Artery Disease Coronary Disease Heart Diseases Hypothermic Cardiopulmonary Bypass Lung Diseases Myocardial Ischemia Postoperative Pulmonary Atelectasis Postoperative Pulmonary Complication Pulmonary Atelectasis Respiratory Tract Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Institut Jantung Negara

Kuala Lumpur, 50400, Malaysia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All patients that undergo general anaesthesia for CABG surgery requiring neuromuscular blockade of either rocuronium or cis-atracurium

Exclusion criteria

  • Recent history of pulmonary infection four weeks before surgery
  • Exposed to both neuromuscular blockade within 24 hours perioperatively
  • Patients intubated or on tracheostomies pre-operatively
  • Any missing or incomplete data

Treatment and study plan

Rocuronium Bromide 10 MG/ML

Drug

Comparative

Other names: Esmeron

Nimbex 10 MG in 5 ML Injection

Drug

Comparative

Other names: Cis-atracurium

Primary outcomes

  1. Incidence of postoperative pulmonary complication

    Time frame: 6 months

    Which neuromuscular relaxant is associated with lesser postoperative pulmonary complication

Secondary outcomes

  1. Ventilation hours in ICU

    Time frame: 6 months

    Ventilation hours from ICU admission from OR to extubation

  2. Requirements for Non-invasive ventilation

    Time frame: 6 months

    NIV duration

  3. Incidence of postoperative atrial fibrillation

    Time frame: 6 months

    Incidence of postoperative atrial fibrillation

Sponsors and collaborators

Lead sponsor

Institut Jantung Negara

Other

Registry information

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Oct 26, 2023
Registry last updated
Nov 28, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.